HBV ANTISENSE INHIBITORS
First Claim
1. An antisense compound comprising a modified antisense oligonucleotide wherein nucleotides in the oligonucleotide are connected by internucleotide linkages having a nucleobase sequence of nucleotides of any of SEQ ID NOs:
- 14-22,or a salt, solvate, hydrate or ester thereof.
3 Assignments
0 Petitions
Accused Products
Abstract
Antisense oligomers useful for modulating hepatitis B virus infections, and for the treatment of hepatitis B virus (HBV) and hepatitis B virus-related conditions in animals including humans. More particularly, antisense oligomers with modified nucleotides for treatment of HBV in animals, more particularly antisense oligomers comprising 2′O-4′C-methylene-bridged sugars, or nucleotides with other 2′O-4′C bridged sugars, also known as locked nucleic acids (LNA), for treatment of HBV in animals, and more particularly for treatment of HBV in humans.
-
Citations
40 Claims
-
1. An antisense compound comprising a modified antisense oligonucleotide wherein nucleotides in the oligonucleotide are connected by internucleotide linkages having a nucleobase sequence of nucleotides of any of SEQ ID NOs:
- 14-22,
or a salt, solvate, hydrate or ester thereof. - View Dependent Claims (2, 3, 4, 5, 6, 13, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40)
according to claim 13 to a mammal infected with hepatitis B virus; monitoring for presence of HBeAg plus HBeAb in a serum sample of the mammal;
ormonitoring for presence of HBsAg in a serum sample of the mammal, such that the absence of HBeAg plus the presence of HBeAb in the serum sample if monitoring HBeAg as the determinant for seroconversion, or the absence of HBsAg in the serum sample if monitoring HBsAg as the determinant for seroconversion, as determined by currently available detection limits of commercial ELISA systems, is indication of seroconversion in the mammal.
- 14-22,
-
37. A method according to claim 16, wherein administration is selected from oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal or intratracheal administration.
-
38. The compound of claim 1 wherein at least one nucleoside comprises a modified nucleobase.
-
39. A method for reducing an amount of HBV DNA in a mammal infected with a hepatitis B virus, the method comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need thereof so as to reduce the amount of HBV DNA in the mammal infected with the hepatitis B virus, compared to the amount of HBV DNA in the mammal before treatment.
-
40. A method according to claim 39, wherein the amount of DNA is reduced 90% compared to amount before administration of the compound.
- 7. An antisense compound comprising a modified antisense oligonucleotide consisting of from 10 to 100 nucleotides in length connected by internucleotide linkages having a nucleobase sequence comprising from 10 to 30 contiguous nucleotides having a nucleobase sequence that is essentially complementary to any one of SEQ ID NOs. 1-13.
-
10-12. -12. (canceled)
- 28. (canceled)
Specification